Citigroup Cuts Agilon Health (NYSE:AGL) Price Target to $0.75

Agilon Health (NYSE:AGL) had its target price decreased by Citigroup from $0.85 to $0.75 in a research report report published on Tuesday,Benzinga reports. Citigroup currently has a neutral rating on the stock.

Several other equities research analysts have also recently weighed in on the company. BTIG Research reissued a “neutral” rating on shares of Agilon Health in a research note on Friday, December 12th. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. Barclays decreased their price target on Agilon Health from $1.00 to $0.50 and set an “underweight” rating on the stock in a report on Friday, February 27th. Wells Fargo & Company raised their price target on Agilon Health from $1.00 to $1.50 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agilon Health in a research report on Wednesday, January 21st. Three investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $2.18.

Agilon Health Price Performance

Agilon Health stock opened at $0.66 on Tuesday. Agilon Health has a 52-week low of $0.34 and a 52-week high of $6.08. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The firm’s fifty day moving average is $0.71 and its 200 day moving average is $0.84. The company has a market cap of $273.77 million, a price-to-earnings ratio of -0.69 and a beta of 0.11.

Agilon Health (NYSE:AGL) last posted its earnings results on Wednesday, February 25th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.19). The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.46 billion. Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%. Sell-side analysts forecast that Agilon Health will post -0.59 EPS for the current fiscal year.

Institutional Trading of Agilon Health

Several institutional investors and hedge funds have recently made changes to their positions in AGL. Wealthcare Advisory Partners LLC acquired a new stake in shares of Agilon Health in the third quarter worth approximately $26,000. LPL Financial LLC lifted its holdings in Agilon Health by 213.4% in the 4th quarter. LPL Financial LLC now owns 44,055 shares of the company’s stock valued at $30,000 after purchasing an additional 30,000 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Agilon Health during the 2nd quarter worth $31,000. CIBC Bancorp USA Inc. acquired a new stake in Agilon Health during the 3rd quarter worth $34,000. Finally, Krilogy Financial LLC purchased a new stake in shares of Agilon Health during the fourth quarter worth $34,000.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.